Lumos Diagnostics

♦️ Capital Raise Complete ♦️ Lumos Diagnostics has announced that it has successfully completed the retail component of its Entitlement Offer, which raised approximately A$6.9 million. The institutional component of the Entitlement Offer successfully completed last month raised approximately A$3.1 million, bringing the total amount raised under the Entitlement Offer to A$10.0 million. Lumos CEO and Managing Director, Doug Ward said, “We appreciate the strong backing from all those investors who participated in this capital raise, particularly Tenmile and Ryder Capital, who are aligned with our vision to address unmet needs in human health. These funds provide Lumos with solid backing to drive the growth of our business.” Read the ASX release 👉 https://lnkd.in/eiDtqA2U    $LDX #LDX #Lumos #healthcare #pointofcare #diagnostics #AMR #antimicrobialresistance #innovation  #invest

Lumos Diagnostics has been awarded US$2,984,571 from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response. The primary purpose of this funding is to support a planned Clinical Laboratory Improvement Amendments (CLIA)-waiver clinical study and regulatory submission for Lumos’ FebriDx® Bacterial/Non-Bacterial test. Lumos Diagnostics CEO and MD, Doug Ward, commented: “We are honoured to have the opportunity to partner with BARDA on the CLIA waiver study and regulatory submission for FebriDx®. BARDA’s expertise and the associated funding will support our objective of expanding the test's utility - from its current use case in moderate/high complexity labs - to US CLIA-waived point-of-care settings, including physician offices, urgent care clinics, or other outpatient clinics. Should this goal be achieved, FebriDx’s ability to improve antibiotic stewardship will be vastly expanded.” Read the ASX release 👉 https://bit.ly/LDX_BARDA $LDX #LDX #Lumos #pointofcare #diagnostics #respiratoryhealth #clinicalstudy #healthcare

🖊 New Contract   Lumos Diagnostics has been awarded placement of their novel POC test, FebriDx®, on the MediGroup national contract, making it available to all their members in the United States. FebriDx has been cleared for use in the US by healthcare professionals with patients presenting in urgent care or emergency care settings and is intended to be used in conjunction with clinical signs and symptoms, including other clinical and laboratory findings, to evaluate patients for acute respiratory infection. MediGroup is the single largest non-acute care group purchasing organization (GPO) in the United States. Lumos CEO and Managing Director, Doug Ward said: “We are very pleased to see FebriDx® added to MediGroup’s national contract. As a leading group purchasing organization, MediGroup has more than 30,000 members, including a mix of moderately complex labs and CLIA waived locations. This is a key relationship for us as we continue to build out our distribution coverage for FebriDx®.” Read the ASX release 👉 https://lnkd.in/gE9cxqvr $LDX #LDX #Lumos #pointofcare #diagnostics #rapidtest #respiratoryhealth #innovation

➖ Milestone Achieved ➖   Lumos Diagnostics has announced it has successfully completed the first “Phase 2 Milestone” in the development of a new fetal fibronectin (fFN) test for leading women’s health company, Hologic, Inc. Lumos signed two new Agreements with Hologic in January 2024 - an Intellectual Property agreement valued at US$10.0 million and a Development Agreement valued at US$4.7 million. The focus of the Development Agreement is to create a next generation version of Hologic’s on-market fFN diagnostic product for pre-term birth. This includes adapting the test for use on the Lumos proprietary reader platform, with improved connectivity options. Lumos Diagnostics CEO and MD, Doug Ward, commented: “We are proud to achieve this next milestone, which demonstrates the strong progress Lumos and Hologic are making in developing a new fetal fibronectin (fFN) test. We're excited by the results of the work program to date and are pressing ahead with the remainder of the scoped work under Phase 2 of the agreement.” Read the ASX release 👉 https://lnkd.in/gngpdYf8 $LDX #LDX #ASX #innovation #medicaldevice #diagnostic #healthcare #innovation #pointofcare

🗞 AMR in the news More headlines are circulating following the release of a new study published in The Lancet earlier this week, estimating nearly 40 million people could die from antibiotic-resistant infections by 2050. This particular article explores shifting links in AMR-related deaths over nearly three decades, public health improvements, and the all-important need for new antibiotics and improved diagnostics too. 'Given the high variability of AMR burden by location and age, it is important that interventions combine infection prevention, vaccination, minimisation of inappropriate antibiotic use in farming and humans, and research into new antibiotics to mitigate the number of AMR deaths that are forecasted for 2050.' See it here 👉 https://lnkd.in/gzJ8BRg5 $LDX #LDX #AMR #superbugs #antibioticresistance #publichealth #Lumos #pointofcare #diagnostics

➖ Investor Briefings ➖ Lumos’ management team would like to invite existing and potential investors to attend in-person presentations in Melbourne and Sydney next week. Lumos CEO Doug Ward and CFO Barrie Lambert will visit Melbourne and Sydney to discuss the Company’s full-year results in detail, outline key priorities for the coming year, and provide investors with further business updates. Briefing details: ▶ MELBOURNE – Tuesday 24 September at 12pm Vault 1 Room, Workspace 365  Level 14, 333 Collins Street, Melbourne VIC  Light lunch, tea and coffee will be available after the presentation. ▶ SYDNEY – Wednesday 25 September at 12pm Bond Business Centre, Midnight Rambler Room, Workspace 365  Level 4/20 Bond Street, Sydney NSW  Light lunch, tea and coffee will be available after the presentation. To register your interest to attend either briefing, please email Pip Thorn via pip.thorn@irdepartment.com.au by COB on Friday 20 September 2024. $LDX #LDX #ASX #innovation #medicaldevice #diagnostic #healthcare #innovation #pointofcare

📰 AMR in the News A new study from the Global Research on Antimicrobial Resistance Project estimates nearly 40 million people could die from antibiotic-resistant infections by 2050 – a grim reminder of the urgency of the ongoing superbug crisis. ‘Using statistical modeling, the researchers produced estimates of deaths and illnesses attributable to AMR by 2050 in three scenarios: if the current climate continues, if new potent antibiotic drugs are developed to target resistant pathogens, and if the world has improved quality of healthcare for infections and better access to antibiotics. ‘The forecasts show that deaths from antimicrobial resistance will increase by 2050 if measures are not in place to improve access to quality care, powerful antibiotics and other resources to reduce and treat infections.’ In the face of this growing emergency, Lumos' point-of-care diagnostic tests offer a vital tool. By aiding clinicians in making informed treatment decisions and reducing unnecessary antibiotic prescriptions, our tests can help preserve the effectiveness of existing antibiotics while the world awaits new solutions. Read more about the study 👉 https://lnkd.in/ggXhyqAj $LDX #LDX #AMR #superbugs #antibioticresistance #publichealth #Lumos #pointofcare #diagnostics 

➖ Milestone Achieved ➖   Lumos Diagnostics has announced it has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to distribute FebriDx® in the United States (US). FebriDx is a rapid point-of-care (POC) respiratory test which delivers results in 10 minutes from a fingerstick blood sample. In July 2023, the US Food and Drug Administration cleared FebriDx to be marketed in the US as an aid in the diagnosis of bacterial acute respiratory infection and differentiation from non-bacterial etiology. Lumos Diagnostics CEO and MD, Doug Ward, said: “We are very pleased to announce this partnership with Fisher Healthcare for FebriDx distribution,” said Lumos Diagnostics CEO and MD, Doug Ward. “We look forward to working together to accelerate the growth of FebriDx via their network of customers across the US.” Read the ASX release 👉 https://lnkd.in/gf_4rEZX $LDX #LDX #ASX #innovation #medicaldevice #diagnostic #healthcare #innovation #pointofcare

➖ Capital Raise ➖ Lumos Diagnostics has today announced that it has successfully completed the institutional component of its recently announced A$10.0 million equity raising - raising a total of approximately A$3.1 million from institutional and sophisticated investors.   Read the ASX release 👉 https://lnkd.in/g_zh6yTW    $LDX #LDX #Lumos #healthcare #pointofcare #diagnostics #AMR #antimicrobialresistance #innovation #invest

Greetings from Philadelphia! 👋🏻 Lumos Diagnostics is proud to be participating in the World AMR Congress, currently underway in Philadelphia. We're having insightful discussions with healthcare professionals and industry leaders about the critical role rapid diagnostics play in combating antimicrobial resistance, and how FebriDx® can help reduce unnecessary antibiotic prescriptions and improve patient care. If you're attending the Congress, please visit us at booth #415 to learn more about FebriDx® and our commitment to fighting AMR. $LDX #LDX #Lumos #AMR #antibioticresistance #rapidtest #diagnostics #healthcare #WorldAMRCongress